IceCure Medical (ICCM) furnishes H1 2025 results, MD&A and press release

Rhea-AI Filing Summary

IceCure Medical Ltd. filed a Form 6-K as a foreign private issuer, providing investors with a package of information on its performance for the first half of 2025. The report furnishes unaudited interim condensed consolidated financial statements as of and for the six months ended June 30, 2025.

It also includes management’s discussion and analysis of financial condition and results of operations for the same period, plus a press release titled “IceCure Reports Financial & Operational Results for the First Half of 2025.” These materials are incorporated by reference into existing Form F-3 and Form S-8 registration statements.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025 (Report No. 2)

Commission file number: 001-40753

ICECURE MEDICAL LTD.

(Translation of registrant’s name into English)

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F          ☐ Form 40-F

CONTENTS

This  Report of Foreign Private Issuer on Form 6-K, or Report, of IceCure Medical Ltd. (the “Company”) consists of the Company’s: (i) Unaudited Interim Condensed Consolidated Financial Statements as of and for the six months ended June 30, 2025, which are attached hereto as Exhibit 99.1; (ii) Management’s Discussion and Analysis of Financial Condition and Results of Operations as of and for the six months ended June 30, 2025, which is attached hereto as Exhibit 99.2; and (iii) a press release issued by the Company on August 13, 2025 titled “IceCure Reports Financial & Operational Results for the First Half of 2025”, which is attached hereto as Exhibit 99.3.

This Report (other than the fourth, fifth and sixth paragraphs of Exhibit 99.3 furnished herewith) is incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-258660 and 333-267272) and Form S-8 (Registration Nos. 333-270982, 333-264578, 333-262620, and 333-281587), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit No.
99.1		IceCure Medical Ltd.’s Unaudited Interim Condensed Consolidated Financial Statements as of and for the Six Months Ended June 30, 2025.
99.2		IceCure Medical Ltd.’s Management’s Discussion and Analysis of Financial Condition and Results of Operations as of and for the Six Months Ended June 30, 2025.
99.3		Press release titled “IceCure Reports Financial & Operational Results for the First Half of 2025 ”.
EX-101.INS		Inline XBRL Taxonomy Instance Document
EX-101.SCH		Inline XBRL Taxonomy Extension Schema Document
EX-101.CAL		Inline XBRL Taxonomy Calculation Linkbase Document
EX-101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
EX-101.LAB		Inline XBRL Taxonomy Label Linkbase Document
EX-101.PRE		Inline XBRL Taxonomy Presentation Linkbase Document
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	IceCure Medical Ltd.
Date: August 13, 2025	By:	/s/ Eyal Shamir
		Name:	Eyal Shamir
		Title:	Chief Executive Officer

2

FAQ

What does IceCure Medical Ltd. (ICCM) disclose in this August 2025 Form 6-K?

IceCure Medical Ltd. furnishes a Form 6-K that packages its unaudited interim condensed consolidated financial statements for the six months ended June 30, 2025, management’s discussion and analysis for the same period, and a related press release covering first-half 2025 financial and operational results.

Which financial statements are included in IceCure Medical’s (ICCM) August 2025 Form 6-K?

The Form 6-K includes IceCure Medical’s unaudited interim condensed consolidated financial statements as of and for the six months ended June 30, 2025. These statements give a mid-year snapshot of the company’s consolidated financial position and results, complementing its annual Form 20-F reporting.

Does the IceCure Medical (ICCM) Form 6-K include management’s analysis of results?

Yes. Alongside the financial statements, IceCure Medical provides management’s discussion and analysis of financial condition and results of operations for the six months ended June 30, 2025. This narrative explains the company’s performance drivers, liquidity, and operating trends over the first half of 2025.

What press release is attached to IceCure Medical’s (ICCM) August 2025 Form 6-K?

The Form 6-K attaches a press release titled “IceCure Reports Financial & Operational Results for the First Half of 2025.” This release summarizes the company’s financial and operational developments for that period, complementing the more detailed financial statements and management analysis exhibits.

How is this IceCure Medical (ICCM) Form 6-K used in its registration statements?

The Form 6-K, excluding the fourth, fifth, and sixth paragraphs of the attached press release, is incorporated by reference into IceCure Medical’s existing Form F-3 and Form S-8 registration statements. This makes the mid-year 2025 information part of the disclosure package supporting those registrations.

Which SEC registration statements incorporate this IceCure Medical (ICCM) Form 6-K?

This report is incorporated by reference into IceCure Medical’s Form F-3 registration statements with numbers 333-258660 and 333-267272, and its Form S-8 registration statements with numbers 333-270982, 333-264578, 333-262620, and 333-281587, enhancing those filings with the latest mid-year 2025 information.